This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / uniQure Securities Fraud Class Action
Business class action

uniQure Securities Fraud Class Action

Analysis based on 10 articles · First reported Feb 19, 2026 · Last updated Mar 19, 2026

Sentiment
-60
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against UniQure for alleged securities fraud has caused a significant negative impact on UniQure's stock price, which plummeted over 49%. This event highlights the risks associated with biotechnology companies' clinical trial disclosures and regulatory interactions, potentially increasing investor scrutiny on similar firms.

Biotechnology Legal Services
Event Summary

A securities fraud class action lawsuit has been filed against UniQure by Kessler Topaz Meltzer & Check on behalf of investors who purchased UniQure ordinary shares between September 24, 2025, and October 31, 2025. The lawsuit alleges that UniQure made material misstatements and omissions concerning its Huntington's disease gene therapy drug, AMT-130, specifically regarding its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the United States — Food and Drug Administration. Investors learned the truth on November 3, 2025, when UniQure revealed that the United States — Food and Drug Administration no longer agreed that the existing data was adequate for a BLA submission, leading to an unclear timeline for approval and a more than 49% drop in UniQure's share price.

Entities Involved
stock
UniQure
UniQure is the defendant in a securities fraud class action lawsuit due to alleged material misstatements and omissions regarding its Huntington's disease gene therapy drug, AMT-130, which led to a significant drop in its share price.
Importance 100.0 Sentiment -70.0
per
Jonathan Naji
Importance 0.0 Sentiment 0.0
priv
Kessler Topaz Meltzer & Check
Importance 0.0 Sentiment 0.0
govactor
United States — United States District Court for the Northern District of California
Importance 0.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Importance 0.0 Sentiment 0.0
Relationships
UniQure related ↔ United States — Food and Drug Administration
Jonathan Naji attorney ↔ Kessler Topaz Meltzer & Check Jonathan Naji is an attorney at the law firm Kessler Topaz Meltzer & Check, serving as a public contact for investors in
Jonathan Naji related ↔ United States — United States District Court for the Northern District of California
Kessler Topaz Meltzer & Check related ↔ United States — United States District Court for the Northern District of California
United States — United States District Court for the Northern District of California related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.